IMADORK
Nov 19, 6:46 PM
$ARDX My hunch is ARDX won’t buy another Bio or an early stage pipeline asset in the near future. Reason is they have put all their eggs in the “Will be profitable in 2027” basket. Repeatedly. Taking on a new asset or company would be an expense and create a new execution risk alongside the current payor friction(unless the new asset is accretive…). Imo until they go profitable and generate large cash flows they won’t bite on other assets. Timing is everything. Doing so now, the market could interpret it as taking eyes off the ball.
0 replies